Rochester, Minn.-based Mayo Clinic entered into an agreement with DNA sequencing company Veritas Genetics to integrate whole-genome sequencing into clinical care, the company confirmed Jan. 8.
The collaboration is funded by the Mayo Clinic Center for Individualized Medicine and led by the center's medical director, Dr. Keith Stewart.
Under the agreement, healthy patients who participate in a Mayo Clinic research study will receive a whole-genome sequencing screening test through Veritas Genetics' flagship product, myGenome. Mayo Clinic researchers will offer clinical feedback to the Veritas Genetics team.
Mayo Clinic, which will also become a Veritas shareholder, says it will use any revenue it receives as a result of the collaboration to support its nonprofit mission to drive healthcare.